<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869893</url>
  </required_header>
  <id_info>
    <org_study_id>CIN_MRCPStudy_001</org_study_id>
    <nct_id>NCT02869893</nct_id>
  </id_info>
  <brief_title>MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics</brief_title>
  <official_title>Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ChiRhoClin, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The National Pancreas Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research study is to learn more about the pancreas. The investigators want
      to use Magnetic Resonance Cholangiopancreatography (MRCP) to learn more about the size of a
      normal pancreas. MRCP is a special kind of MRI exam that produces detailed images of the
      pancreas. The investigators also want to figure out how much fluid the pancreas releases in
      response to secretin. Secretin is a chemical in the body that causes the pancreas to release
      fluid that helps with digestion. Secretin is used during the MRCP (MR-PFT) to help identify
      dysfunction of the pancreas. MR elastography (MRE) will be used to measure how hard the
      pancreas is. MRE is a special kind of MRI that uses vibrations to image tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction/Methods: Pancreatic fibrosis is the end stage of chronic pancreatitis (CP),
      which leads to loss of acinar volume and secretory capacity, and ultimately pancreatic
      insufficiency (PI). CP and congenital PI affect the pediatric population, and are both
      increasingly recognized in children. PI has serious negative implications on a child's growth
      and health but, if diagnosed early, PI can be treated, minimizing the detrimental effects of
      PI. Currently, direct pancreatic function testing (PFT) via collection of pancreatic fluid is
      the &quot;gold standard&quot; for diagnosis of PI but it is an invasive testing that may require
      sedation or general anesthesia. Magnetic resonance cholangiopancreatography (MRCP) with
      secretin administration (MR-PFT) and MR elastography (MRE) may allow non-invasive, and
      potentially early diagnosis of CP and PI. Currently, however, normative data with which to
      compare MR-PFT and MRE results in pediatric patients with suspected CP/PI is not available.

      Aims: The investigators propose to determine the normal range for secreted pancreatic fluid
      volume in response to secretin administration and determine the normal range for pancreatic
      parenchymal stiffness in a pediatric population that is not affected by pancreatic disease.
      To date, the investigators have validated their MRCP technique and have successfully
      performed both MR-PFT and MRE in CP patients; however normative data is essential for
      validation of our non-invasive technique.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2016</start_date>
  <completion_date type="Actual">April 6, 2017</completion_date>
  <primary_completion_date type="Actual">April 6, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total secreted fluid volume as measured by MR-PFT</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pancreatic stiffness as measured by MR elastography</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric measurements of pancreatic parenchymal volume</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Healthy Participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MRCP with Secretin and MR elastography will be performed on all participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secretin</intervention_name>
    <arm_group_label>Healthy Participants</arm_group_label>
    <other_name>ChiRhoStim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects between the ages of 6 and 15.9 years.

          2. Subjects without a documented history of (or suggestive of) pancreatic disease

        Exclusion Criteria:

          1. History of pancreatic disease, liver disease, intra-abdominal neoplasm, abdominal
             inflammatory process such as inflammatory bowel disease (IBD), or systemic illness
             that may affect pancreatic state (e.g. cystic fibrosis).

          2. Subjects with surgical hardware/implanted devices making them ineligible for MRI (e.g.
             pacemaker or other implanted medical device not approved for MRI).

          3. Subjects who require any form of sedation or general anesthesia for MRI.

          4. Subjects unable to breath-hold for the required 15-20 second imaging sequence.

          5. Subjects who are pregnant or less than 12 months post-partum.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maisam Abu-El-Haija, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Trout, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Amann ST, Yadav D, Barmada MM, O'Connell M, Kennard ED, Anderson M, Baillie J, Sherman S, Romagnuolo J, Hawes RH, Alkaade S, Brand RE, Lewis MD, Gardner TB, Gelrud A, Money ME, Banks PA, Slivka A, Whitcomb DC. Physical and mental quality of life in chronic pancreatitis: a case-control study from the North American Pancreatitis Study 2 cohort. Pancreas. 2013 Mar;42(2):293-300. doi: 10.1097/MPA.0b013e31826532e7.</citation>
    <PMID>23357924</PMID>
  </reference>
  <reference>
    <citation>Schwarzenberg SJ, Bellin M, Husain SZ, Ahuja M, Barth B, Davis H, Durie PR, Fishman DS, Freedman SD, Gariepy CE, Giefer MJ, Gonska T, Heyman MB, Himes R, Kumar S, Morinville VD, Lowe ME, Nuehring NE, Ooi CY, Pohl JF, Troendle D, Werlin SL, Wilschanski M, Yen E, Uc A. Pediatric chronic pancreatitis is associated with genetic risk factors and substantial disease burden. J Pediatr. 2015 Apr;166(4):890-896.e1. doi: 10.1016/j.jpeds.2014.11.019. Epub 2014 Dec 30.</citation>
    <PMID>25556020</PMID>
  </reference>
  <reference>
    <citation>Somaraju UR, Solis-Moya A. Pancreatic enzyme replacement therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2014 Oct 13;(10):CD008227. doi: 10.1002/14651858.CD008227.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Nov 23;11:CD008227.</citation>
    <PMID>25310479</PMID>
  </reference>
  <reference>
    <citation>Arya VB, Senniappan S, Demirbilek H, Alam S, Flanagan SE, Ellard S, Hussain K. Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism. PLoS One. 2014 May 19;9(5):e98054. doi: 10.1371/journal.pone.0098054. eCollection 2014.</citation>
    <PMID>24840042</PMID>
  </reference>
  <reference>
    <citation>Conwell DL, Zuccaro G Jr, Vargo JJ, Morrow JB, Obuchowski N, Dumot JA, Trolli PA, Burton A, O'laughlin C, Van Lente F. An endoscopic pancreatic function test with cholecystokinin-octapeptide for the diagnosis of chronic pancreatitis. Clin Gastroenterol Hepatol. 2003 May;1(3):189-94.</citation>
    <PMID>15017490</PMID>
  </reference>
  <reference>
    <citation>Abu Dayyeh BK, Conwell D, Buttar NS, Kadilaya V, Hart PA, Baumann NA, Bick BL, Chari ST, Chowdhary S, Clain JE, Gleeson FC, Lee LS, Levy MJ, Pearson RK, Petersen BT, Rajan E, Steen H, Suleiman S, Banks PA, Vege SS, Topazian M. Pancreatic juice prostaglandin e2 concentrations are elevated in chronic pancreatitis and improve detection of early disease. Clin Transl Gastroenterol. 2015 Jan 29;6:e72. doi: 10.1038/ctg.2014.23.</citation>
    <PMID>25630864</PMID>
  </reference>
  <reference>
    <citation>Pelley JR, Gordon SR, Gardner TB. Abnormal duodenal [HCO3-] following secretin stimulation develops sooner than endocrine insufficiency in minimal change chronic pancreatitis. Pancreas. 2012 Apr;41(3):481-4. doi: 10.1097/MPA.0b013e31823a4c33.</citation>
    <PMID>22228105</PMID>
  </reference>
  <reference>
    <citation>Sendler M, Beyer G, Mahajan UM, Kauschke V, Maertin S, Schurmann C, Homuth G, Völker U, Völzke H, Halangk W, Wartmann T, Weiss FU, Hegyi P, Lerch MM, Mayerle J. Complement Component 5 Mediates Development of Fibrosis, via Activation of Stellate Cells, in 2 Mouse Models of Chronic Pancreatitis. Gastroenterology. 2015 Sep;149(3):765-76.e10. doi: 10.1053/j.gastro.2015.05.012. Epub 2015 May 19.</citation>
    <PMID>26001927</PMID>
  </reference>
  <reference>
    <citation>Conwell DL, Zuccaro G, Purich E, Fein S, Vanlente F, Vargo J, Dumot J, O'laughlin C, Trolli P. The effect of moderate sedation on exocrine pancreas function in normal healthy subjects: a prospective, randomized, cross-over trial using the synthetic porcine secretin stimulated Endoscopic Pancreatic Function Test (ePFT). Am J Gastroenterol. 2005 May;100(5):1161-6.</citation>
    <PMID>15842594</PMID>
  </reference>
  <reference>
    <citation>Conwell DL, Zuccaro G, Purich E, Fein S, Vargo JJ, Dumot JA, VanLente F, Lopez R, Trolli P. Comparison of endoscopic ultrasound chronic pancreatitis criteria to the endoscopic secretin-stimulated pancreatic function test. Dig Dis Sci. 2007 May;52(5):1206-10. Epub 2007 Mar 27.</citation>
    <PMID>17387611</PMID>
  </reference>
  <reference>
    <citation>Zuccaro P, Stevens T, Repas K, Diamond R, Lopez R, Wu B, Conwell DL. Magnetic resonance cholangiopancreatography reports in the evaluation of chronic pancreatitis: a need for quality improvement. Pancreatology. 2009;9(6):764-9. doi: 10.1159/000201304. Epub 2010 Jan 21.</citation>
    <PMID>20110743</PMID>
  </reference>
  <reference>
    <citation>Sainani NI, Kadiyala V, Mortele K, Lee L, Suleiman S, Rosenblum J, Wang W, Banks PA, Conwell DL. Evaluation of Qualitative Magnetic Resonance Imaging Features for Diagnosis of Chronic Pancreatitis. Pancreas. 2015 Nov;44(8):1280-9. doi: 10.1097/MPA.0000000000000466.</citation>
    <PMID>26465953</PMID>
  </reference>
  <reference>
    <citation>Balci NC, Smith A, Momtahen AJ, Alkaade S, Fattahi R, Tariq S, Burton F. MRI and S-MRCP findings in patients with suspected chronic pancreatitis: correlation with endoscopic pancreatic function testing (ePFT). J Magn Reson Imaging. 2010 Mar;31(3):601-6. doi: 10.1002/jmri.22085.</citation>
    <PMID>20187202</PMID>
  </reference>
  <reference>
    <citation>Shi Y, Glaser KJ, Venkatesh SK, Ben-Abraham EI, Ehman RL. Feasibility of using 3D MR elastography to determine pancreatic stiffness in healthy volunteers. J Magn Reson Imaging. 2015 Feb;41(2):369-75. doi: 10.1002/jmri.24572. Epub 2014 Feb 5.</citation>
    <PMID>24497052</PMID>
  </reference>
  <reference>
    <citation>Itoh Y, Takehara Y, Kawase T, Terashima K, Ohkawa Y, Hirose Y, Koda A, Hyodo N, Ushio T, Hirai Y, Yoshizawa N, Yamashita S, Nasu H, Ohishi N, Sakahara H. Feasibility of magnetic resonance elastography for the pancreas at 3T. J Magn Reson Imaging. 2016 Feb;43(2):384-90. doi: 10.1002/jmri.24995. Epub 2015 Jul 7.</citation>
    <PMID>26149267</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Secretin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

